Pfizer Inc. (NYSE:PFE) – Leerink Swann decreased their FY2019 earnings per share (EPS) estimates for Pfizer in a report released on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the firm will earn $2.78 per share for the year, down from their previous forecast of $2.85. Leerink Swann also issued estimates for Pfizer’s FY2020 earnings at $2.68 EPS.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS.
Other equities research analysts have also issued research reports about the stock. Argus reissued a “buy” rating and issued a $39.00 price target on shares of Pfizer in a report on Sunday, August 28th. Jefferies Group reissued a “buy” rating and issued a $42.00 price target (up previously from $41.00) on shares of Pfizer in a report on Tuesday, June 14th. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target on the stock. in a report on Tuesday, June 28th. Citigroup Inc. reissued a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, August 3rd. Finally, Barclays PLC reissued an “equal weight” rating and issued a $34.00 price target on shares of Pfizer in a report on Tuesday, August 2nd. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.78.
Pfizer (NYSE:PFE) traded up 0.32% during midday trading on Thursday, reaching $34.26. 12,937,101 shares of the company’s stock traded hands. The firm’s 50-day moving average is $34.68 and its 200 day moving average is $33.90. The firm has a market cap of $207.81 billion, a PE ratio of 30.37 and a beta of 0.87. Pfizer has a 52-week low of $28.25 and a 52-week high of $37.39.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.50%. Pfizer’s dividend payout ratio is currently 95.24%.
Hedge funds have recently made changes to their positions in the stock. Nelson Roberts Investment Advisors LLC boosted its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares in the last quarter. Stelac Advisory Services LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $110,000. Tuttle Tactical Management LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $117,000. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares in the last quarter. Finally, Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. 69.65% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.